Image: orderpharma.co.uk
Avandia
Advair
Paxil
What next for GlaxoSmithKline?
Avodart!
A recent Study finds possible heart risk with prostate drug.
Full results of a big study testing a drug for preventing prostate cancer show a higher risk of heart failure, a surprise finding that could dampen enthusiasm for expanding its use.
On Monday, GlaxoSmithKline PLC asked the federal Food and Drug Administration to approve its drug Avodart as a cancer preventive for men at higher-than-normal risk of the disease. The drug is already sold for urinary problems, and no heart failure risks have been seen with that use, doctors say.
Results of a study testing it as a cancer preventive were given at a medical conference last year, but the heart risk information was not known at that time, a Glaxo spokeswoman said. Full results are being published in Thursday’s New England Journal of Medicine.
FULL STORY
GlaxoSmithKline are currently the subject of litigation in the UK regarding their antidepressant drug, Seroxat.
The claim is being pursued by several hundred U.K. patients who said it was difficult to stop taking the antidepressant Seroxat [known as Paxil in the US].
Glaxo have stated, "We believe there is no merit in this litigation."
More recently, GlaxoSmithKline PLC decided to voluntarily pull its zinc-containing lines of Poligrip denture cream from the market and stop all advertising and manufacture of the creams, as suits pile up in the multidistrict litigation over neurological problems from excessive zinc levels caused by denture products.
Latest Share Prices:
GLAXOSMITHKLINE (GSK.L) 4:35pm: 1,257.00 p DOWN 8.50 (0.67%)
Fid
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
No comments: